Skip to content

Erector Spina Plane Block in Laparoscopic Sleeve Gastrectomy Surgery

The Effect of Erector Spina Plane Block on Pulmonary Functions and Analgesic Consumption in Laparoscopic Sleeve Gastrectomy Surgery

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04039321
Enrollment
40
Registered
2019-07-31
Start date
2019-08-01
Completion date
2019-12-04
Last updated
2019-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

Erector spina plane block, Laparoscopic sleeve gastrectomy, Obesity, Postoperative pain, Pulmonary functions

Brief summary

The aim of the study is to evaluate the effect of erector spina plane (ESP) block on pulmonary functions and postoperative analgesic consumption in patients undergoing bariatric surgery.

Detailed description

Optimal pain management is very important in obese patients. In the postoperative period, narcotic analgesics are often used to pain management. However, the use of narcotic analgesics in the postoperative period causes many undesirable adverse effects, especially sedation, dizziness, constipation, nausea, vomiting, muscle rigidity, tolerance, and respiratory depression. The morbidly obese patients treated with narcotic analgesics increased risk for adverse effects such as atelectasis, hypoxemia, and postoperative ileus. Consequently, these are caused postoperative pulmonary complications, hypoxemia and longer lenght of hospital stay. Multimodal analgesia including local and regional anesthesia is recommended for morbidly obese patients. In recent years, the ultrasound (USG) guided ESP block has been frequently used to eliminate postoperative pain and reduce narcotic analgesic use. In the literature, it has been shown that bilateral USG guided ESP block provides effective analgesia and decrease the analgesia requirements after laparoscopic cholecystectomy. Some case series and case reports has also been reported that ESP block provides effective analgesia after abdominal and bariatric surgeries. The aim of the study is to evaluate the effect of erector spina plane (ESP) block on pulmonary functions and postoperative analgesic consumption in patients undergoing bariatric surgery. For this purpose, ASA II-III, patients over 18 years of age, BMI 40-60 kg/m2 and elective bariatric surgery planned patients will be included in the study.

Interventions

USG probe will be placed in a longitudinal parasagittal orientation 3 cm lateral to T7 spinous process. The erector spinae muscles will be identified hyperechoic transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 21-gauge 10-cm needle was inserted using an in-plane superior-to-inferior approach or an outplane approach. Following confirmation of the correct position of the needle with 5 ml normal saline, a dose of 20 ml %0.25 bupivacaine will be administered. The same procedure will be performed at the other site (totally 40 ml %0.25 bupivacaine). Standard pain follow up and monitorization will be performed.

DRUGControl group

The patients in this group will be performed no block. Standard pain follow up and monitorization will be performed.

Sponsors

Antalya Training and Research Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* American Society of Anesthesiology (ASA) II-III * 18-65 years * body mass index (BMI) 40-60 kg/m2 * elective bariatric surgery

Exclusion criteria

* ASA ≥4 * under 18 years of age or over 65 years of age * declining to give written informed consent * have neurological and/or psychiatric disorders * cooperation cannot be established * accompanying laparoscopic cholecystectomy or paraumbilical hernia repair * history of bariatric surgery * the block cannot be applied due to bleeding disorders or localized skin infection at the injection site * with hepatic, neuromuscular, cardiac and/or renal failure * history of allergy to the local anesthetics * patients undergoing open surgery * patients with severe obstructive or restrictive lung disease

Design outcomes

Primary

MeasureTime frameDescription
pulmonary function testperioperativePulmonary function test will be performed for all of them in the day before operation and 24 hours after the operation. Pulmonary function tests will assess via a portable spirometer with the patient in the sitting or semi-recumbent position.
analgesia consumption24 hourspostoperative 24 hours

Secondary

MeasureTime frameDescription
Postoperative Numeric Rating Scale (NRS) scorepostoperative 0, 1, 3, 6, 9, 12, 18, 24 hourspostoperative pain assessment will be performed using NRS score (NRS 0=no pain, NRS 10= most severe possible). The NRS scores will be recorded at postoperative 0, 1, 3, 6, 9, 12, 18 and 24 hours
arterial blood gasesduring the surgeryintraoperative

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026